The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenue | 3,794 | - |
| Total operating expenses | 163,536 | - |
| Total other income, net | 4,679 | - |
| Net loss | -50,582 | -104,481 |
| Stock-based compensation expense | 12,747 | 12,006 |
| Non cash lease expense | 2,334 | 4,761 |
| Depreciation expense | 1,881 | 3,564 |
| Change in fair value of short-term investment related party | 1,454 | -1,561 |
| Amortization of premiums and discount on short-term investments | 574 | 575 |
| Collaboration receivable related party | -120 | 120 |
| Prepaid expenses and other current assets | -1,297 | -652 |
| Accounts payable | 3,038 | -1,461 |
| Deferred income taxes | - | 0 |
| Accrued expenses and other current liabilities | -1,070 | -1,690 |
| Accrued settlement payment related party | 0 | 0 |
| Deferred revenue related party | -1,175 | -2,433 |
| Lease liabilities | -1,601 | -2,053 |
| Net cash used in operating activities | -35,039 | -90,269 |
| Maturities of investments | 42,431 | 14,250 |
| Purchases of investments | 134,306 | 55,227 |
| Purchases of property and equipment | 247 | 3,994 |
| Return (payments) of security deposits | 0 | - |
| Net cash (used in) provided by investing activities | -92,122 | -44,971 |
| Proceeds from follow-on offering, net of issuance costs | 138,380 | 0 |
| Proceeds from research and development funding liability | 6,000 | 6,000 |
| Net proceeds from stock option exercises | 373 | 0 |
| Proceeds from espp offerings | 0 | 197 |
| Proceeds from issuance of common stock under the bms securities purchase agreement related party | 0 | - |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | 0 | 0 |
| Net cash provided by financing activities | 144,753 | 6,197 |
| Net change in cash, cash equivalents, and restricted cash | 17,592 | -129,043 |
| Cash and cash equivalents at beginning of period | 196,538 | - |
| Cash and cash equivalents at end of period | 85,087 | - |
Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. (PRME)